The A/R hasn't changed, that's the problem. I was expecting 1500 units sold and at least reported in the first quarter A/R. The only thing I can think of why they didn't report is because they sell VitaStem though BiogenX and there maybe a one quarter delay in reporting. The reason CEO Otiko stated why the fins are late, was because they where waiting on a third party. Maybe they reported without the third party info. The third party being BiogenX.
I can only assume what happened, but it's the best I can justify.
The next quarter should then post the 1500 units of VitaStem Sales and the $150K deposit(50%) from the $250,000 initial sales agreement with Vage Nigeria Ltd.
Lots of upside.
News 
Market Data 
Discover 
